Arsenale and Amphasys Sign Joint Development Agreement
A new partnership combines real-time single-cell analysis with AI-driven biomanufacturing to close one of the field's longest-standing data gaps.
Scale-up in biomanufacturing fails for many reasons.
One of the most persistent is a lack of real-time information at the cellular level — the absence of a clear signal about what cells are actually doing inside the bioreactor, at the moment decisions get made.
That gap has consequences. It extends development cycles, inflates the cost of scale-up, and forces teams into cycles of trial and error that slow the entire path from lab to industrial production.
On March 9, 2026, Arsenale and Amphasys signed a Joint Development Agreement to address it directly.
What each company brings
Amphasys has spent years building precision tools for single-cell analysis. Their impedance flow cytometry technology measures cell properties in real time, without labels or disruption to the process — giving engineers high-resolution insight into what cells are actually doing inside the bioreactor, as it happens.
Arsenale is building an integrated biomanufacturing platform that connects precision micro-fermentation hardware, continuous data capture, and Design@Scale — a proprietary AI platform that predicts industrial-scale outcomes from lab-scale data and improves with every run.
The underlying logic of the platform has always been the same: hardware exists to generate data, and data is what makes the AI work. The quality of the signal determines the quality of the prediction.
What the agreement creates
By integrating Amphasys's cell analysis into Arsenale's platform, the JDA creates something the field has not had before: a direct, continuous link between cellular behavior and industrial-scale process performance.
The combined system will feed higher-resolution biological signals into Design@Scale at the moment decisions are being made — enabling more accurate predictions, faster iteration, and a tighter feedback loop between organism behavior and process outcomes.
The anticipated results: shorter development cycles, more predictable scale-up, and less reliance on empirical repetition.
A step toward the platform the bioeconomy needs
Biomanufacturing at industrial scale requires more than capable organisms and sophisticated equipment. It requires systems that learn — that accumulate knowledge across every run, every scale, every condition, and use that knowledge to reduce the cost and uncertainty of what comes next.
This partnership is one piece of that system taking shape.
More information at amphasys.com and arsenale.bio.